The effect of supplemental L-arginine on tolerance development during continuous transdermal nitroglycerin therapy (Q43939856)

28 November 2017

The effect of supplemental L-arginine on tolerance development during continuous transdermal nitroglycerin therapy (English)

1 reference

28 November 2017

John O Parker

1

1 reference

28 November 2017

John D Parker

2

1 reference

28 November 2017

Robert W Caldwell

3

1 reference

28 November 2017

Bernice Farrell

4

1 reference

28 November 2017

Wayne H Kaesemeyer

5

1 reference

28 November 2017

language of work or name

English

0 references

publication date

1 April 2002

1 reference

Journal of the American College of Cardiology

28 November 2017

1 reference

28 November 2017

39

1 reference

28 November 2017

7

1 reference

28 November 2017

1199-1203

1 reference

Nitrate therapy for stable angina pectoris

28 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901729-1

7 January 2021

Acute and chronic antianginal efficacy of continuous twenty-four-hour application of transdermal nitroglycerin. Steering Committee, Transdermal Nitroglycerin Cooperative Study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901729-1

7 January 2021

Tolerance to organic nitrates: evidence, mechanisms, clinical relevance, and strategies for prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901729-1

7 January 2021

Intermittent transdermal nitroglycerin therapy in the treatment of chronic stable angina

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901729-1

7 January 2021

Risk of rebound phenomenon during nitrate withdrawal

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901729-1

7 January 2021

Counter-regulatory responses to continuous and intermittent therapy with nitroglycerin

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901729-1

7 January 2021

Transdermal nitroglycerin efficacy in patients with chronic stable angina pectoris as related to sympathetic and renin-angiotensin-aldosterone activity

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901729-1

7 January 2021

Effects of diuretic therapy on the development of tolerance during continuous therapy with nitroglycerin

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901729-1

7 January 2021

Zaprinast, but not dipyridamole, reverses hemodynamic tolerance to nitroglycerin in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901729-1

7 January 2021

Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901729-1

7 January 2021

Role of L-arginine in the vascular actions and development of tolerance to nitroglycerin

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901729-1

7 January 2021

Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901729-1

7 January 2021

Effects of long-term nitroglycerin treatment on endothelial nitric oxide synthase (NOS III) gene expression, NOS III-mediated superoxide production, and vascular NO bioavailability

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901729-1

7 January 2021

Endothelial nitric oxide synthase is a site of superoxide synthesis in endothelial cells treated with glyceryl trinitrate

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901729-1

7 January 2021

The two-period cross-over clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901729-1

7 January 2021

Efficacy and safety of extended-release isosorbide mononitrate for stable effort angina pectoris

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901729-1

7 January 2021

Lack of pharmacologic tolerance and rebound angina pectoris during twice-daily therapy with isosorbide-5-mononitrate

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901729-1

7 January 2021

Eccentric dosing with isosorbide-5-mononitrate in angina pectoris.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901729-1

7 January 2021

Intermittent transdermal nitroglycerin monotherapy in stable exercise-induced angina: a comparison with a continuous schedule

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901729-1

7 January 2021

Intermittent transdermal nitroglycerin therapy. Decreased anginal threshold during the nitrate-free interval

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901729-1

7 January 2021

Effect of supplemental oral L-arginine on exercise capacity in patients with stable angina pectoris

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901729-1

7 January 2021

Evidence for a role of endothelin 1 and protein kinase C in nitroglycerin tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901729-1

7 January 2021

Therapy with nitroglycerin increases coronary vasoconstriction in response to acetylcholine

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901729-1

7 January 2021

Nitroglycerin withdrawal increases endothelium-dependent vasomotor response to acetylcholine.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901729-1

7 January 2021

Evidence supporting abnormalities in nitric oxide synthase function induced by nitroglycerin in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901729-1

7 January 2021

Dietary supplement with vitamin C prevents nitrate tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901729-1

7 January 2021

Evidence for a causal role of the renin-angiotensin system in nitrate tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901729-1

7 January 2021

Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901729-1

7 January 2021

Effects of NO donors and synthase agonists on endothelial cell uptake of L-Arg and superoxide production

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901729-1

7 January 2021

A Caveolar Complex between the Cationic Amino Acid Transporter 1 and Endothelial Nitric-oxide Synthase May Explain the “Arginine Paradox”

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901729-1

7 January 2021

The alpha-amino group of L-arginine mediates its antioxidant effect

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901729-1

7 January 2021

Nitric oxide and another potent vasodilator are formed from NG-hydroxy-L-arginine by cultured endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2901729-1

7 January 2021

10.1016/S0735-1097(02)01729-1

Identifiers

DOI

1 reference

28 November 2017

1 reference